Get the Stockscreener App
1.04
6.12%
0.06
Pre-market:
1.01
-0.03
-2.88%
Revelation Biosciences Inc stock is traded at $1.04, with a volume of 38,303.
It is up +6.12% in the last 24 hours and down -5.02% over the past month.
Revelation Biosciences Inc is a clinical-stage life science company focused on rebalancing inflammation to optimize health using its proprietary formulation, Gemini. The company is developing a pipeline of potential products based on Gemini, which is its proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD), a synthetic version of monophosphoryl lipid A (MPLA). PHAD is a small fragment of lipopolysaccharide (LPS) that stimulates TLR4 and leads to controlled production of multiple cytokines and chemokines that modulate the innate and adaptive immune response. The company operates through one reportable segment focused on the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system.
See More
Previous Close:
$0.98
Open:
$0.96
24h Volume:
38,303
Relative Volume:
0.60
Market Cap:
$4.06M
Revenue:
-
Net Income/Loss:
$-9.87M
P/E Ratio:
-0.0264
EPS:
-39.4678
Net Cash Flow:
$-8.76M
1W Performance:
-0.95%
1M Performance:
-5.02%
6M Performance:
-70.51%
1Y Performance:
-65.74%
1-Day Range:
$0.9501
$1.07
1-Week Range:
$0.95
$1.07
52-Week Range:
$0.875
$12.88
Revelation Biosciences Inc Stock (REVB) Company Profile
Name
Revelation Biosciences Inc
Sector
Industry
Phone
650-800-3717
Address
4660 LAJOLLA VILLAGE DRIVE, SAN DIEGO
Compare REVB vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
REVB
Revelation Biosciences Inc
|
1.04 | 3.83M | 0 | -9.87M | -8.76M | -39.47 |
VRTX
Vertex Pharmaceuticals Inc
|
499.65 | 124.70B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
631.81 | 66.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
912.46 | 55.17B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
192.62 | 38.71B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
293.52 | 38.90B | 4.29B | 577.22M | 641.34M | 4.2086 |
Revelation Biosciences Inc Stock (REVB) Latest News
Price to earnings forward of Revelation Biosciences, Inc. – BOATS:REVBW - TradingView
Revelation Biosciences, Inc. Actuals & Estimates (NASDAQ:REVB) - TradingView
Revelation Biosciences, Inc. Actuals & Estimates (BOATS:REVB) - TradingView
REVB Forecast — Price Target — Prediction for 2027 - TradingView
Revelation Biosciences Inc (REVBW) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Revelation Biosciences Amends Executive Agreements and Bylaws, Announces CEO and CFO Changes – June 2026 - Minichart
Revelation Biosciences Updates Executive Contracts, Shareholder Actions - TipRanks
Revelation Biosciences updates employment agreements for CEO James Rolke and CFO Chester S. Zygmont, III - TradingView
Revelation Biosciences (NASDAQ: REVB) expands CEO/CFO protections and secures reverse split authority - Stock Titan
Revelation Biosciences Inc (REVB) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Revelation Biosciences Inc (REVBW) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Revelation Biosciences Inc (REVBW) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Revelation Biosciences Inc (REVBW) Institutional Confidence - TradingKey
Revelation Biosciences Inc (REVBW) Valuation: PE, PB & Fair Value Analysis - TradingKey
Revelation Biosciences Inc (REVBW) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Revelation Biosciences Inc (REVB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Revelation Biosciences Inc (REVB) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Revelation Biosciences Inc (REVB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Revelation Biosciences Inc (REVB) Valuation: PE, PB & Fair Value Analysis - TradingKey
Revelation Biosciences Inc (REVBW) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Revelation Biosciences Inc (REVBW) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Revelation Biosciences Inc - TradingKey
Revelation Biosciences Inc (REVB) Institutional Confidence - TradingKey
Revelation Biosciences Inc (REVB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Revelation Biosciences Inc (REVB) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Revelation Biosciences Inc (REVB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Revelation Biosciences, Inc. Financial Disclosures & SEC Filings - TradingView
REVB SEC FilingsRevelation Biosciences 10-K, 10-Q, 8-K Forms - Stock Titan
REVB Q1 2026 Earnings: EPS Misses Estimates by Wide Margin; No Revenue ReportedEPS Revision Trend - newsline.com
REVB Q1 2026 Earnings: Wider-than-Expected Loss Amid Pre-Revenue StageCFO Commentary Report - newsline.com
Revelation Biosciences forms advisory board for AKI trial - Investing.com
Revelation Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Newark Advocate
Revelation Biosciences expands AKI advisory board - Investing.com UK
Revel Releases Updated Corporate Presentation and Posts It to Website - TradingView
Revelation Biosciences (NASDAQ: REVB) furnishes new corporate presentation - Stock Titan
Revelation Biosciences expands AKI advisory board By Investing.com - Investing.com South Africa
Revelation Biosciences Expands Acute Kidney Injury Advisory Board - Rutland Herald
REVB Q1 2026 Earnings: Wider-Than-Expected Loss Highlights Pre-Revenue StageSubscription Growth Report - newsline.com
Revelation Biosciences (REVB) Shows Minimal Movement as Shares Trade Near Key SupportTime Weighted Price - newsline.com
REVB Q1 2026 Earnings: Significant EPS Miss as Cash Burn Continues Without RevenueReturn On Assets - thelegaladvocate.com
Revelation Biosciences (REVB) Inches Higher, Holding Above Key Support at $1.02Bear Pennant - The Legal Advocate
REVB Q1 2026 Earnings: Significant EPS Miss Amid Early-Stage DevelopmentEarnings Revision Downgrade - The Legal Advocate
REVB Q1 2026 Earnings: Staggering EPS Miss Highlights Ongoing Clinical Development CostsBook Value Growth - The Legal Advocate
Revelation Biosciences Inc. (REVB) Edges Lower, Maintains Support Near $1.01Exhaustion Gap - The Legal Advocate
REVB Q1 2026 Earnings: Wider-than-Expected Loss Highlights Pre-Revenue ChallengesEarnings Outlook Update - newsline.com
Revelation Biosciences (REVB) Faces Slight Decline as Key Support Levels Are TestedWave Extension - The Legal Advocate
Revelation Biosciences Q1 2026 Earnings: EPS Miss Highlights Ongoing Pre-Revenue StageStock Analysis Community - Newser
Revelation Biosciences Inc. (REVB) Q1 2026 Earnings: Wider-than-Expected Loss as Pre-Revenue Biotech Continues DevelopmentEarnings Yield Spread - Newser
Revelation Biosciences (REVB) Consolidates Near Key Support at $1.03Institutional Grade Picks - Newser
Revelation Biosciences Inc Stock (REVB) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):